Novel therapeutic potential in targeting microtubules by nanoparticle albumin-bound paclitaxel in hepatocellular carcinoma

International Journal of Oncology

Volumn 38, Issue 3, 2011, Pages 721-731

  Zhou, Qian ^a   Ching, Arthur K K ^a   Leung, Wilson K C ^a   Szeto, Carol Y Y ^b   Ho, Shuk Mei ^b   Chan, Paul K S ^a   Yuan, Yun Fei ^c   Lai, Paul B S ^a   Yeo, Winnie ^a   Wong, Nathalie ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Expression array; Hepatocellular carcinoma; nab paclitaxel; STMN1; Therapy

Indexed keywords

DOCETAXEL; DOXORUBICIN; NANOPARTICLE; PACLITAXEL;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL LINE; CELL STRAIN; CLINICAL ARTICLE; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TARGETING; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MALIGNANT TRANSFORMATION; MICROTUBULE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; XENOGRAFT;

AGED; ALBUMINS; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITORY CONCENTRATION 50; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROARRAY ANALYSIS; MICROTUBULES; MIDDLE AGED; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NANOPARTICLES; PACLITAXEL; PROTEIN BINDING; TUBULIN MODULATORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79952030682     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.902     Document Type: Article

References (45)

1. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2: 533-543, 2001.
2. Yeo W, Mok TS, Zee B, et al: A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97: 1532-1538, 2005. (Pubitemid 41631953)
3. Gish RG, Porta C, Lazar L, et al: Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol 25: 3069-3075, 2007.
4. Ramanathan RK, Belani CP, Singh DA, et al: Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A California Consortium (CCC-P) Trial. J Clin Oncol 24: 4010, 2006.
5. O'Dwyer PJ, Giantonio BJ, Levy DE, Kauh JS, Fitzgerald DB and Benson AB: Gefitinib in advanced unresectable hepatocellular carcinoma: results from the Eastern Cooperative Oncology Group's Study E1203. J Clin Oncol 24: 4143, 2006.
6. Cheng AL, Kang YK, Chen ZD, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34, 2009.
7. Ng IOL, Liu CL, Fan ST and Ng M: Expression of P-glycoprotein in hepatocellular carcinoma - a determinant of chemotherapy response. Am J Clin Pathol 113: 355-363, 2000. (Pubitemid 30217382)
8. Endicott JA and Ling V: The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58: 137-171, 1989. (Pubitemid 19172967)
9. Park JG, Lee SK, Hong IG, et al: Mdr1 gene-expression - its effect on drug-resistance to doxorubicin in human hepatocellular-carcinoma cell-lines. J Natl Cancer Inst 86: 700-705, 1994.
10. Yokoe T, Tanaka F, Mimori K, Inoue H, Ohmachi T, Kusunoki M and Mori M: Efficient identification of a novel cancer/testis antigen for immunotherapy using three-step microarray analysis. Cancer Res 68: 1074-1082, 2008. (Pubitemid 351272225)
11. Bergamaschi A, Hjortland GO, Triulzi T, et al: Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models. Mol Oncol 3: 469-482, 2009.
12. Zagani R, Hamzaoui N, Cacheux W, et al: Cyclooxygenase-2 inhibitors down-regulate osteopontin and Nr4a2-new therapeutic targets for colorectal cancers. Gastroenterology 137: 1358-1366, 2009.
13. Goto Y, Matsuzaki Y, Kurihara S, et al: A new melanoma antigen fatty acid-binding protein 7, involved in proliferation and invasion, is a potential target for immunotherapy and molecular target therapy. Cancer Res 66: 4443-4449, 2006.
14. Scrideli CA, Carlotti CG, Okamoto OK, et al: Gene expression profile analysis of primary glioblastomas and non-neoplastic brain tissue: identification of potential target genes by oligonucleotide microarray and real-time quantitative PCR. J Neurooncol 88: 281-291, 2008.
15. Nogales E, Wolf SG and Downing KH: Structure of the alpha beta tubulin dimer by electron crystallography. Nature 391: 199-203, 1998. (Pubitemid 28092482)
16. Rowinsky EK: The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 48: 353-374, 1997.
17. Gan YB, Wientjes MG, Schuller DE and Au JLS: Pharmacodynamics of taxol in human head and neck tumors. Cancer Res 56: 2086-2093, 1996. (Pubitemid 26119910)
18. Yen WC, Wientjes MG and Au JLS: Differential effect of taxol in rat primary and metastatic prostate tumors: Site-dependent pharmacodynamics. Pharmaceut Res 13: 1305-1312, 1996. (Pubitemid 26344972)
19. Szebeni J, Alving CR, Savay S, Barenholz Y, Priev A, Danino D and Talmon Y: Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions. Int Immunopharmacol 1: 721-735, 2001. (Pubitemid 32206533)
20. Gelderblom H, Verweij J, Nooter K and Sparreboom A: Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37: 1590-1598, 2001. (Pubitemid 32778603)
21. Green MR, Manikhas GM, Orlov S, Afanasyev B, Makhson AM, Bhar P and Hawkins MJ: Abraxane((R)), a novel Cremophor((R))-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 17: 1263-1268, 2006. (Pubitemid 44288216)
22. Desai N, Trieu V, Yao ZW, et al: Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel. Clin Cancer Res 12: 1317-1324, 2006. (Pubitemid 43342524)
23. Desai NP, Trieu V, Hwang LY, Wu RJ, Soon-Shiong P and Gradishar WJ: Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs 19: 899-909, 2008.
24. Wong N, Chan KYY, Macgregor PF, et al: Transcriptional profiling identifies gene expression changes associated with IFN-alpha tolerance in hepatitis C-related hepatocellular carcinoma cells. Clin Cancer Res 11: 1319-1326, 2005. (Pubitemid 40175786)
25. Chan KYY, Lai PBS, Squire JA, Beheshti B, Wong NLY, Sy SMH and Wong N: Positional expression profiling indicates candidate genes in deletion hotspots of hepatocellular carcinoma. Mod Pathol 19: 1546-1554, 2006. (Pubitemid 44789922)
26. Milross CG, Mason KA, Hunter NR, Chung WK, Peters LJ and Milas L: Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 88: 1308-1314, 1996. (Pubitemid 26301619)
27. Fan WM: Possible mechanisms of paclitaxel-induced apoptosis. Biochem Pharmacol 57: 1215-1221, 1999.
28. Alli E, Yang JM and Hait WN: Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53. Oncogene 26: 1003-1012, 2007.
29. Patil MA, Chua MS, Pan KH, et al: An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma. Oncogene 24: 3737-3747, 2005. (Pubitemid 40826873)
30. Tung CY, Jen CH, Hsu MT, Wang HW and Lin CH: A novel regulatory event-based gene set analysis method for exploring global functional changes in heterogeneous genomic data sets. BMC Genom 10: 26, 2009.
31. Breuhahn K, Vreden S, Haddad R, et al: Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression. Cancer Res 64: 6058-6064, 2004. (Pubitemid 39129404)
32. Wang W, Peng JX, Yang JQ and Yang LY: Identification of gene expression profiling in hepatocellular carcinoma using cDNA microarrays. Dig Dis Sci (In press).
33. Mok TSK, Choi E, Yau D, Johri A, Yeo W, Chan ATC and Wong C: Effects of patupilone (epothilone B; EPO906), a novel chemotherapeutic agent, in hepatocellular carcinoma: an in vitro study. Oncology 71: 292-296, 2006.
34. Nimeiri HS, Singh DA, Kasza K, Taber DA, Ansari RH, Vokes EE and Kinder HL: The epothilone B analogue ixabepilone in patients with advanced hepatobiliary cancers: a trial of the University of Chicago Phase II Consortium. Invest New Drugs (In press).
35. Schiff PB and Horwitz SB: Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA Biol Sci 77: 1561-1565, 1980. (Pubitemid 10073801)
36. Kloover JS, den Bakker MA, Gelderblom H and van Meerbeeck JP: Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br J Cancer 90: 304-305, 2004. (Pubitemid 38250619)
37. Belmont LD and Mitchison TJ: Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules. Cell 84: 623-631, 1996. (Pubitemid 26071742)
38. Mistry SJ and Atweh GF: Stathmin inhibition enhances okadaic acid-induced mitotic arrest - a potential role for stathmin in mitotic exit. J Biol Chem 276: 31209-31215, 2001. (Pubitemid 37384989)
39. Marklund U, Larsson N, Gradin HM, Brattsand G and Gullberg M: Oncoprotein 18 is a phosphorylation-responsive regulator of microtubule dynamics. EMBO J 15: 5290-5298, 1996. (Pubitemid 26336212)
40. Mistry SJ, Li HC and Atweh GF: Role for protein phosphatases in the cell-cycle-regulated phosphorylation of stathmin. Biochem J 334: 23-29, 1998. (Pubitemid 28420966)
41. Price DK, Ball JR, Bahrani-Mostafavi Z, et al: The phosphoprotein Op18/stathmin is differentially expressed in ovarian cancer. Cancer Inves 18: 722-730, 2000.
42. Bieche I, Lachkar S, Becette V, Cifuentes-Diaz C, Sobel A, Lidereau R and Curmi PA: Overexpression of the stathmin gene in a subset of human breast cancer. Br J Cancer 78: 701-709, 1998. (Pubitemid 28418300)
43. Daibata M, Matsuo Y, Machida H, Taguchi T, Ohtsuki Y and Taguchi H: Differential gene-expression profiling in the leukemia cell lines derived from indolent and aggressive phases of CD56(+) T-cell large granular lymphocyte leukemia. Int J Cancer 108: 845-851, 2004. (Pubitemid 38112612)
44. Alli E, Bash-Babula J, Yang JM and Hait WN: Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res 62: 6864-6869, 2002. (Pubitemid 35424074)
45. Wang X, Chen YC, Han QB, et al: Proteomic identification of molecular targets of gambogic acid: Role of stathmin in hepatocellular carcinoma. Proteomics 9: 242-253, 2009.